NONOF - Altimmune falls after Q4 results; obesity drug data released
2024-03-27 08:26:15 ET
More on Altimmune
- Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
- Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
- Thoroughly Derisked, Altimmune Is Now A Great Buy
- Altimmune Q4 2023 Earnings Preview
- Altimmune stock climbs 9% amid Jefferies note on recent sell-off